Antibody-drug conjugates the 21st century magic bullets for cancer /
This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the f...
| Other Authors: | Wang, Jeffrey,, Shen, Wei-Chiang, 1942-, Zaro, Jennica L.,, SpringerLink (Online service) |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
[2015]
|
| Physical Description: |
1 online resource (x, 252 pages) : illustrations (some color). |
| Series: |
AAPS advances in the pharmaceutical sciences series ;
volume 17. |
| Subjects: |
| Summary: |
This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field. |
|---|---|
| Item Description: |
Includes index. Includes bibliographical references at the end of each chapter, and index. Antibody-drug conjugates : a historical review / Wei-Chiang Shen -- Payloads of antibody-drug conjugates / Chalet Tan -- Selecting an optimal antibody for antibody-drug conjugate therapy / Michael Ritchie, Laird Bloom, Gregory Carven and Puja Sapra -- Linker design for antibody-drug conjugates / E. Erica Hong and Ravi Chari -- Formulation development for antibody-drug conjugates / Junyan A. Ji, Jun Liu and Y. John Wang -- Bioanalytical assay for characterization of antibody drug conjugates (ADCs) / Chen Xie and Zhijun Wang -- Pharmacokinetics/pharmacodynamics and disposition of antibody-drug conjugates / Siddharth Sukumaran and Kedan Lin -- Regulatory considerations / Karen J. Cha -- Major ADC companies, current clinical trials, recent patents issued and patent applications, and cost analysis of drug therapy / Jeffrey Wang and Jonathan Hirohiko Watanabe -- Mylotarg : revisiting its clinical potential post-withdrawal / Jennica L. Zaro -- ADCETRIS : a regulatory case study of a new generation antibody-drug conjugate / Bruce W. Hart -- Ado-trastuzumab emtansine / Yun Luo, Jérôme J. Lacroix and Sunil Prabhu -- The antibody-drug conjugate Glembatumumab Vedotin (CDX-011) and its use in treatment of breast cancer / Linda T. Vahdat and Nancy Chan -- Summary and future directions / Jennica L. Zaro, Jeffrey Wang and Wei-Chiang Shen. This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field. English. |
| Physical Description: |
1 online resource (x, 252 pages) : illustrations (some color). |
| Bibliography: |
Includes bibliographical references at the end of each chapter, and index. |
| ISBN: |
9783319130811 3319130811 3319130803 9783319130804 |
| ISSN: |
2210-7371 ; |